- Home
- GTBP vs REVB Comparison
GTBP vs REVB Comparison
Compare GTBP & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- REVB
- Stock Information
- Founded
- GTBP 1965
- REVB 2020
- Country
- GTBP United States
- REVB United States
- Employees
- GTBP N/A
- REVB N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- GTBP Health Care
- REVB Health Care
- Exchange
- GTBP Nasdaq
- REVB Nasdaq
- Market Cap
- GTBP 2.6M
- REVB 2.3M
- IPO Year
- GTBP N/A
- REVB N/A
- Fundamental
- Price
- GTBP $0.74
- REVB $0.87
- Analyst Decision
- GTBP Strong Buy
- REVB
- Analyst Count
- GTBP 1
- REVB 0
- Target Price
- GTBP $11.00
- REVB N/A
- AVG Volume (30 Days)
- GTBP 1.2M
- REVB 121.2K
- Earning Date
- GTBP 11-14-2025
- REVB 11-06-2025
- Dividend Yield
- GTBP N/A
- REVB N/A
- EPS Growth
- GTBP N/A
- REVB N/A
- EPS
- GTBP N/A
- REVB N/A
- Revenue
- GTBP N/A
- REVB N/A
- Revenue This Year
- GTBP N/A
- REVB N/A
- Revenue Next Year
- GTBP N/A
- REVB N/A
- P/E Ratio
- GTBP N/A
- REVB N/A
- Revenue Growth
- GTBP N/A
- REVB N/A
- 52 Week Low
- GTBP $0.54
- REVB $0.83
- 52 Week High
- GTBP $4.10
- REVB $60.48
- Technical
- Relative Strength Index (RSI)
- GTBP 53.14
- REVB 25.66
- Support Level
- GTBP $0.62
- REVB $0.83
- Resistance Level
- GTBP $1.15
- REVB $0.91
- Average True Range (ATR)
- GTBP 0.09
- REVB 0.08
- MACD
- GTBP 0.01
- REVB 0.00
- Stochastic Oscillator
- GTBP 34.74
- REVB 10.03
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).